Biogen acquired exclusive global rights to Vanqua Bio’s preclinical C5aR1 antagonist (VQ‑201), paying $70 million upfront with additional contingent milestones. The deal reflects Biogen’s renewed interest in early‑stage immunology agents and positions the company to pursue complement‑targeted approaches in inflammatory and neuroimmune indications. Company statements framed the transaction as a strategic way to expand Biogen’s immunology pipeline with a mechanism linked to innate immune modulation.